The recent publication of guidance from the National
|
|
- Oscar Thompson
- 6 years ago
- Views:
Transcription
1 216 Clinical Pharmacist May 2009 Vol 1 Several guidelines exist for the identification and treatment of osteoporosis. Patients diagnosed with the condition should be prescribed bisphosphonates, if suitable, in the first instance Osteoporosis treatment and risk assessment For personal use only. Not to be reproduced without permission of the editor (permissions@pharmj.org.uk) By Wasim Baqir, PhD, MRPharmS, Carmel Copeland, DipClinPharm, MRPharmS, and Alan Worsley, PhD, MRPharmS The recent publication of guidance from the National Osteoporosis Guideline Group (NOGG) 1 and two technology appraisals from the National Institute for Health and Clinical Excellence 2,3 has led to a rethink in the way osteoporosis should be managed. Once patients have been identified as being at raised risk of an osteoporotic fracture, preventive measures are needed. The main preventive treatments are bisphosphonates and strontium ranelate. Less frequently used are raloxifene, hormone replacement therapy and teriparatide. This article outlines the available drug therapies and discusses clinical guidance. Calcium and vitamin D Calcium and vitamin D are recognised as having important roles in bone development. Populations deficient in these nutrients show signs of bone abnormalities. Calcium is important in bone remodelling; absorption from the gastrointestinal tract is improved when taken with vitamin D. As a preventive measure alone the evidence base is poor, with the only evidence for sole use being in housebound elderly patients. 4 6 However, it is generally accepted that patients who are taking bone protection treatments should be taking calcium and vitamin D unless sufficient dietary intake is assured. Bisphosphonates Bisphosphonates are now regarded as first-line treatment for primary and secondary prevention of osteoporotic fractures. They act to reduce resorption of bone and increase bone mineral density (BMD) by having an inhibitory action on osteoclast function and activity. Bisphosphonates have a low oral bioavailability ONCE PATIENTS HAVE BEEN IDENTIFIED AS BEING AT RAISED RISK OF AN OSTEOPOROTIC FRACTURE, PREVENTIVE MEASURES ARE NEEDED Wasim Baqir is a pharmacist at the Pharmacy Audit and Research Group, Northumbria Healthcare NHS Trust and School of Pharmacy, University of Sunderland. Carmel Copeland is senior clinical pharmacist in orthopaedics and qualified independent prescriber in orthogeriatrics at Northumbria Healthcare NHS Trust. Alan Worsley is head of pharmacy practice at the School of Pharmacy, University of Sunderland. E: wasim.baqir@nhs.net (approximately 5%), hence specific administration directions need to be followed to ensure that the necessary amount of drug is absorbed from the gastrointestinal tract (see Box 1, p218). Alendronate and risedronate (dosed either daily or weekly) account for most bisphosphonate prescriptions issued in the UK. Other oral bisphosphonates available are disodium etidronate (the original bisphosphonate but rarely used today) and ibandronic acid (available as a monthly dose). Ibandronic acid and zoledronic acid are available as IV infusions, which are given at three-monthly and annual intervals, respectively. Although there is a strong evidence base supporting the use of bisphosphonates to prevent osteoporotic fractures, 7 9 adverse events are common Their use is frequently associated with gastrointestinal side effects. All oral bisphosphonates have caused cases of serious upper-gi damage (eg, oesophageal ulceration). Recently atrial fibrillation has been linked with the IV bisphosphonate zoledronic acid 14 and there has been some suggestion that this could be a group effect. Osteonecrosis of the jaw has also been associated with bisphosphonate use. 15 This may be precipitated in patients Du Cane Medical Imaging SPL Coloured X-ray of the pelvic region of an elderly woman with osteoporosis: the fractured femur (red) was caused by a fall
2 Vol 1 May 2009 Clinical Pharmacist 217 SUMMARY Pharmacological management of osteoporosis includes use of calcium with vitamin D, bisphosphonates, strontium ranelate and hormonal therapies. This article discusses these treatment options and the role pharmacists have in supporting patients with or at risk of developing the disease. It also looks at national guidelines for treatment and prevention of osteoporosis. Current technology appraisals from the National Institute for Health and Clinical Excellence look specifically at primary and secondary prevention for postmenopausal women only. The National Osteoporosis Guideline Group guideline for postmenopausal women and men aged over 50 years provides recommendations for the management of those at high risk of fracture by using a probability assessment tool. who have undergone a dental procedure. There is insufficient evidence to warrant any change in practice but prescribers should warn patients to report any adverse effects following dental procedures. Pharmacists should also be aware that all bisphosphonates can cause severe musculoskeletal and bone pain. 16 This usually resolves when therapy is stopped. Recently the Medicines and Healthcare products Regulatory Agency has warned prescribers to be mindful of insufficiency fractures (atypical stress fractures) with bisphosphonates (especially alendronate). 17 Prescribers are advised to discontinue alendronate and review the patient. Considering that alendronate currently costs the NHS around 20 per annum per patient compared with 250 for risedronate, and both have similar efficacy, the firstline choice should be alendronate. 1 3 Strontium ranelate Strontium ranelate has a dual mechanism of action reducing bone resorption and increasing bone formation. It is licensed for reducing the risk of vertebral and hip fractures in postmenopausal women and is not currently licensed for men. Strontium comes as a powder for reconstitution as an oral mixture and is taken once daily at night. It is recommended that patients also take a calcium and vitamin D product. There is sufficient evidence for the effectiveness of strontium. In one large study including over 5,000 postmenopausal women aged over 70 years, with osteoporosis (T-score < 2.5) and an additional risk factor, a reduction in non-vertebral fractures was seen for strontium compared with placebo (P=0.04) over 36 months. Subgroup analysis showed that, over 36 months, patients who took strontium suffered fewer hip fractures than those who took placebo (P=0.046). 18 In another study of over 1,500 postmenopausal women with at least one vertebral fracture and T-score < 2.5, the incidence of new vertebral fractures was lower in the strontium group than in the placebo group (P<0.001). 19 The most common side effects are nausea and diarrhoea. In clinical trials strontium has been shown to confer a slightly higher risk of venous thromboembolism than placebo. 20 The manufacturers recommend using it with caution for patients at risk of VTE; it may be sensible to prescribe strontium only once patients are successfully remobilised following hip fracture surgery. At a cost of 332 per annum per patient strontium remains a second-line option after alendronate. Hormonal treatments Hormone replacement therapy is no longer recommended for prevention of osteoporosis. It may still be considered for women for whom other options have failed and this should be done under specialist supervision. DESPITE THE STRONG EVIDENCE BASE SUPPORTING THE USE OF BISPHOSPHONATES TO PREVENT OSTEOPOROTIC FRACTURES, ADVERSE EVENTS ARE COMMON
3 218 Clinical Pharmacist May 2009 Vol 1 Box 1: Bisphosphonate treatment advice It is important for patients to take bisphosphonates on an empty stomach at least 30 minutes before food, with plenty of water. Patients should remain in an upright position for 30 minutes after taking the dose to prevent gastro-oesophageal reflux. Until fractures occur osteoporosis is a silent disease and patients may be disinclined to take a medicine that might seem to offer no obvious benefit or that could be associated with adverse effects. Ensuring patients understand their disease and the reasons for specific instructions can help prevent avoidable side effects and improve medicines compliance. It may be necessary in some cases for the pharmacist to suggest alternative treatment options; for example, some patients might be better suited to a once-yearly bisphosphonate injection. Raloxifene Raloxifene is an oestrogen-receptor modulator that acts by selectively binding to oestrogen receptors, having an oestrogen agonist effect on bone. Raloxifene 60mg daily has been shown to reduce vertebral fractures in women who have osteoporosis, or who have had a previous fragility fracture, compared with placebo (relative risk reduction 0.65, 95% confidence interval ). 21 Research has not demonstrated raloxifene s efficacy in preventing non-vertebral or hip fractures. Teriparatide Teriparatide, a fragment of recombinant human parathyroid hormone, acts by stimulating bone formation. It has been shown to reduce non-vertebral and vertebral fractures and is currently only licensed for postmenopausal women with established osteoporosis. The main evidence for teriparatide comes from a randomised controlled trial investigating women with established osteoporosis. 22 Compared with those taking placebo, patients taking teriparatide experienced a reduced risk of vertebral fractures (risk ratio 0.35, CI ) and grouped non-vertebral fractures (0.65, CI ). However, when individual fracture types were considered teriparatide was shown not to be effective at preventing hip and wrist fractures. There are also concerns that bisphosphonates (in particular, alendronate) might reduce the effect of teriparatide. 22 National guidelines Recently three national guidelines for osteoporosis have been published: two technology appraisals from NICE and a guideline from NOGG. As outlined in this section, these guidelines differ in that NOGG considers both genders but not second-line drug treatment, whereas NICE focuses its appraisals on postmenopausal women and includes set criteria for using second-line treatments. Both organisations advocate opportunistic identification of patients with risk factors and not population screening. It should be noted that the Scottish Intercollegiate Guidelines Network published osteoporosis guidelines in BISPHOSPHONATES SHOULD BE TAKEN ON AN EMPTY STOMACH AT LEAST 30 MINUTES BEFORE FOOD, WITH PLENTY OF WATER Primary prevention The NICE technology appraisal 160 relates to the primary prevention of fragility fractures (ie, no previous fracture) in postmenopausal women who have osteoporosis as defined by a T-score of less than 2.5 from dual-energy X-ray absorptiometry (DXA) scanning. 2 NICE s advice is drug-specific: it recommends the
4 220 Clinical Pharmacist May 2009 Vol 1 bisphosphonate alendronate first line for women aged years who have an independent risk factor (IRF) for osteoporosis or an indicator of low BMD (see Box 2, p223), and who are confirmed to have osteoporosis by DXA scan (T-score < 2.5). Alendronate is also recommended first line for: Women aged 75 years and over who have two or more IRFs or indicators of low BMD (BMD measurement not necessary) Younger women (aged years) who have an IRF and who are confirmed to have osteoporosis by DXA scan Postmenopausal women younger than 65 years who have an IRF for fracture and at least one additional indicator of low BMD and who are confirmed to have osteoporosis by DXA scan Max Blain Dreamstime.com NICE makes specific recommendations for secondand third-line treatment. Risedronate, etidronate and strontium are only to be considered in cases of intolerance to alendronate and if the patients meet criteria based on a combination of T-score, age and number of IRFs. Raloxifene is not recommended for the primary prevention of osteoporotic fragility fractures in postmenopausal women. In contrast to NICE s recommendations, the NOGG guidance covers a broader range of primary and secondary risk factors for osteoporosis and suggests that a patient s risk of fracture should be calculated using risk tables or the World Health Organization Fracture Risk Assessment Tool (available at management is based on that risk. As with NICE s advice, the NOGG guideline recommends alendronate 70mg weekly as first-line treatment because of the medicine s strong evidence base and low price. However, it makes no specific recommendations for second-line therapy, simply stating that other bisphosphonates, strontium ranelate or raloxifene may be appropriate treatment options. NOGG also suggests that teriparatide should be restricted to veryhigh-risk patients, especially for vertebral fractures. Secondary prevention The NICE technology appraisal 161 refers to the secondary prevention of fragility fractures in postmenopausal women who have osteoporosis and have a previous fragility fracture. It states that alendronate should be used first line for postmenopausal women who have had one or more fragility fracture and osteoporosis confirmed by a T-score below 2.5. Women aged 75 years and over who have had a previous fracture can start treatment with alendronate without DXA scanning if the managing clinician considers DXA scanning inappropriate. This is in contrast to the NOGG guidance, which recommends that all women with previous fragility fractures should receive treatment without any further assessment of BMD measurement. NICE gives specific recommendations for teriparatide: as an alternative to bisphosphonates and strontium ranelate for a particular subset of patients. In both of its technology appraisals NICE assumes that women have adequate calcium intake and are not vitamin replete and Women aged 75 years or over may not need a bone scan to diagnose osteoporosis recommends calcium and vitamin D supplementation if this is not the case. Which guideline? The NOGG guideline covers multiple risk factors and offers an easy-to-use interface to calculate risk of fracture and base treatment on that risk. Conversely, NICE only considers three clinical risk factors and five indicators of low BMD in the primary prevention technology appraisal and only previous fractures in the secondary prevention appraisal. Arguably, the NICE guidance is also more complicated for practitioners to apply, with tables based on T-scores, IRFs and body mass index used to decide which second- and third-line treatments should be used. NOGG covers men and women over 50 years, whereas NICE restricts its advice to postmenopausal women. None of the existing guidance documents cover falls and, as discussed, these are a significant risk factor for fractures. The NOGG guideline offers an approach to managing patients that is similar to that for primary and secondary prevention of cardiovascular disease. Patients risk can be easily assessed and the management guidelines are clear. By following NOGG guidelines clinicians can meet the first-line treatment recommendations in NICE TA160 and TA161. NICE s second- and third-line treatment recommendations were contested by the pharmaceutical industry and patient groups but, following a ruling in February 2009, these currently remain as published. Deciding which set of guidance to follow will have implications for resources. Clearly the NOGG guideline is going to identify a larger number of patients at risk compared with the technology appraisals from NICE. Nonetheless, it can be argued that NICE stratifies those at higher risk and most in need of management. Furthermore, following NICE is a requirement for NHS organisations in England and Wales. NICE is planning to produce a clinical guideline on osteoporosis.
5 Vol 1 May 2009 Clinical Pharmacist 223 Pharmacist involvement Frail elderly patients are especially vulnerable to falls, which often lead to fractures. Polypharmacy can increase the likelihood of drug-induced side effects (which can contribute to falls) and patient non-compliance (making osteoporosis treatment ineffective). Medication reviews can highlight such issues for individual patients. [The contributions of a pharmacist to falls prevention in an outpatient clinic are described in an article on page 235.] Clinical pharmacists in hospitals will have contact with patients with osteoporosis across many specialisms. All pharmacists should be aware of risk factors for osteoporosis and falls and be willing to manage or advise on treatment. For example, respiratory pharmacists will often see patients who are at a high risk of osteoporosis secondary to regular use of oral corticosteroids. Similarly, pharmacists working in primary care can identify and manage patients at risk. Community pharmacists could help to identify patients with risk factors either through medicines use reviews or health promotion campaigns (similar to those for diabetes, blood pressure and cholesterol testing offered by some pharmacies). Patient group directions or independent prescribing could allow pharmacists in the community to initiate treatment alongside detailed counselling. Pharmacists can provide information about appliances and aids designed to reduce falls risk, for example walking aids (sticks, Zimmer frames, etc) or hip protectors (external padding incorporated into specially designed underwear). Hip protectors can help reduce the impact of a fall and also improve the confidence of a patient hesitant to walk after falling. Pharmacists should be aware of any local help available to reduce hazard risks in the home. For example, in Box 2: Comparison of NICE and NOGG advice NICE Covers Postmenopausal women Risk factors considered Previous fragility fractures (secondary prevention) Parental history of hip fracture Alcohol intake of 4 units/day Rheumatoid arthritis Indicators of low bone mineral density Low body mass index (<22) Ankylosing spondylitis Crohn s disease Prolonged immobility Untreated early menopause NICE = National Institute for Health and Clinical Excellence technology appraisals (TA160 and TA161) NOGG = National Osteoporosis Guideline Group guideline NOGG Covers Males and females >50 years of age Risk factors considered Previous fragility fractures (secondary prevention) Low body mass index (<19) Parental history of hip fracture Current glucocorticoid treatment (any oral dose for three months or more) Current smoker Alcohol intake of 3 units/day Secondary causes of osteoporosis Rheumatoid arthritis Untreated hypogonadism Prolonged immobility Organ transplantation Type 1 diabetes mellitus Hyperthyroidism Gastrointestinal disease Chronic liver disease Chronic obstructive pulmonary disease Northumberland the Fit, involved, safe and healthy, through investment in sustainable community networks (FISHNETS) project aims to support independent living of older people in the community and promote healthy and active ageing. As well as providing falls prevention education and training, the initiative provides home improvements through access to home help and physical activity programmes. References 1 National Osteoporosis Guideline Group. Osteoporosis: Clinical guideline for prevention and treatment Executive_Summary.pdf (accessed 28 March 2009). 2 National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. October (accessed 15 April 2009). 3 National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. October (accessed 15 April 2009). 4 Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New England Journal of Medicine 1992;327: Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005;330: Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365: Scottish Intercollegiate Guidelines Network. Management of osteoporosis. June (accessed 15 April 2009). 8 Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. Journal of Clinical Endocrinology and Metabolism 2006;91: Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. Journal of Bone and Mineral Research 2005;20: Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Archives of Internal Medicine 2000;160: Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research 2004;19: MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of Internal Medicine 2008;148: Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clinic Proceedings 2002;77: Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007;356: Medicines and Healthcare products Regulatory Agency. Bisphosphonates: osteonecrosis of the jaw. Drug Safety Update 2007;1(3):7. (accessed 15 April 2009). 16 US Food and Drug Administration. Information for healthcare professionals: Bisphosphonates. 7 January (accessed 15 April 2009). 17 Medicines and Healthcare products Regulatory Agency. Bisphosphonates: atypical stress fractures. Drug Safety Update 2009;2(8):8. (accessed 15 April 2009). 18 Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Journal of Clinical Endocrinology and Metabolism 2005;90: Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine 2004;350: Servier Laboratories Ltd. Protelos. Summary of product characteristics. March (accessed 15 April 2009). 21 Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: NHS Clinical Knowledge Summaries. Osteoporosis treatment. Evidence for teriparatide in the treatment of osteoporosis in postmenopausal women. (accessed 12 March 2009).
Summary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationUnderstanding NICE guidance. NICE technology appraisal guidance advises on when and how drugs and other treatments should be used in the NHS.
Understanding NICE guidance Information for people who use NHS services Alendronate, etidronate, risedronate, strontium ranelate and raloxifene for preventing bone fractures in postmenopausal women with
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationIssue date: October Review date: July 2010
Issue date: October 2008 Review date: July 2010 Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More information1. UK List Price of Zoledronic acid (Zoledronate) 5 mg (Aclasta )
Novartis Pharmaceuticals UK Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Dr C M Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence
More informationEndocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat
Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni Hot topics in osteoporosis How long to treat Dott. Bruno Madeo bruno.madeo@unimore.it www.endocrinologia.unimore.it/on-line/home.html
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationTechnology appraisal guidance Published: 27 October 2008 nice.org.uk/guidance/ta160
Raloxifene for the primary prevention ention of osteoporotic fragility fractures in postmenopausal women Technology appraisal guidance Published: 27 October 2008 nice.org.uk/guidance/ta160 NICE 2018. All
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE
CASES AUTH/1803/2/06 and AUTH/1804/2/06 PROCTER & GAMBLE and SANOFI-AVENTIS v ROCHE and GLAXOSMITHKLINE Bonviva Once Monthly slide kits Procter & Gamble and Sanofi-Aventis complained jointly about two
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday
Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for
More informationAnalyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness
Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness of risedronate and strontium ranelate in those people who would be treated with generic
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab for the prevention of osteoporotic fractures in Issued: October 2010 guidance.nice.org.uk/ta204 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper Quality standard topic: Osteoporosis Output: Prioritised quality improvement
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationDenosumab for the prevention of osteoporotic fractures in postmenopausal women
Issue date: October 2010 Denosumab for the prevention of osteoporotic fractures in postmenopausal women This guidance was developed using the single technology appraisal process NICE technology appraisal
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464
Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationGuidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION should be recommended
Guidance for the administration of Denosumab (Prolia ) in Primary Care GENERAL INFORMATION Denosumab is suitable for patients with established osteoporosis for both primary and secondary fracture prevention
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer
Oxford University Hospitals Guidelines for Adjuvant Bisphosphonate treatment for Post-Menopausal Women with Early Breast Cancer Category: Summary: Guideline Adjuvant Bisphosphonate treatment for Post-Menopausal
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationCortical bone After age 40, gradually decreases % yearly, in both men and women Postmenopausally, loss accelerates to 2-3% yearly
Osteoporosis POOLE, K.E.S. & COMPSTON, J.E. (2006): Osteoporosis and its management. BMJ 333:1251-6. Physiology Cortical bone After age 40, gradually decreases 0.3-0.5% yearly, in both men and women Postmenopausally,
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationAdministration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
Administration of Denosumab (PROLIA ) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures 2017 18 1. Purpose of Agreement This agreement outlines the expectations
More informationUpdate on the treatment of post-menopausal osteoporosis
Published Online May 12, 2008 Update on the treatment of post-menopausal osteoporosis Zoë Cole, Elaine Dennison, and Cyrus Cooper * MRC Epidemiology Resource Centre, University of Southampton, Southampton
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationNorth Central London Joint Formulary Committee
North Central London Joint Formulary Committee Calcium + vitamin D supplementation for the prevention of osteoporotic fragility fractures Disclaimer This guideline is registered at North Central London
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationPrevention of Osteoporotic Hip Fracture
Prevention of Osteoporotic Hip Fracture Dr Law Sheung Wai 8th July 2007 Associate Consultant Spine team / Orthopedic Rehabilitation Department of Orthopedics and Traumatology NTE Cluster 1 Objectives Problems
More informationA response by Servier to the Statement of Reasons provided by NICE
A response by Servier to the Statement of Reasons provided by NICE Servier gratefully acknowledges the Statement of Reasons document from NICE, and is pleased to provide information to assist NICE in its
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationAssessment and management of glucocorticoid-induced osteoporosis
PRESCRIBING IN PRACTICE n Assessment and management of glucocorticoid-induced osteoporosis Gerald Tracey and Tehseen Ahmed Glucocorticoid-induced osteoporosis (GIO) is the most prevalent form of secondary
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More information